63326-69-2

Upstream product

• 3386-32-1 n-octadecyl p-toluenesulfonate 
• 86334-56-7 1-octadecyloxy-3-trityloxy-propan-2-ol 
• 98-59-9 p-toluenesulfonyl chloride 
• 16725-43-2 4-(n-octadecyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 76-83-5 trityl chloride 
• 544-62-7 batyl alcohol 

Downstream Products

• 63326-70-5 2-fluoro-1-octadecyloxy-3-trityloxy-propane 
• 99790-92-8 3-octadecyloxy-2-aminopropane-1-ol 
• 99790-83-7 3-octadecyloxy-2-phthalimido-1-trityloxypropane 
• 108225-24-7 3-benzyloxy-2-hydroxypropyl octadecyl ether 
• 16245-97-9 octadecyl glycidyl ether 
• 179458-13-0 1-(1-Octadecyloxymethyl-2-trityloxy-ethyl)-1H-[1,2,4]triazole 
• 179458-12-9 1-(1-Octadecyloxymethyl-2-trityloxy-ethyl)-1H-imidazole 
• 124133-84-2 Toluene-4-sulfonic acid 1-hydroxymethyl-2-octadecyloxy-ethyl ester 

Relevant academic research and scientific papers

Aminoheterocycle-substituted glycerols

Aminoheterocycle-substituted glycerols of Formula I are disclosed: STR1 wherein one of A, B or C is --X--R, wherein X is --O-- or --S--, and R is a substituted or unsubstituted C12-24 alkyl or alkenyl, the substituent being one or more of halo,

Heteroaryl-substituted deoxy glycerols and antibacterial and antiviral compositions containing the same

Heteroaryl-substituted deoxy glycerols represented by the general Formulas Ia, Ib and Ic: STR1 wherein: X is oxygen (--O--) or sulfur (--S--); R is substituted or unsubstituted straight or branched chain C1-30 alkyl or alkenyl, provided that a double bond of the alkenyl does not originate at the carbon atom bound to the X substituent; Het is a 5- to 9-membered heteroaryl mono- or bicyclic ring system having no more than 1 carbonyl carbon in the ring system, with 1 to 4 nitrogen atoms as the sole heteroatoms, one of which nitrogens is bonded to the glycero carbon; and Y is hydroxyl (--OH) or thiol (--SH), pharmaceutical compositions containing the same, and methods of using the compounds, are disclosed. The compounds exhibit antiviral and antibacterial activities.

Heteroaryl-Substituted Deoxy Glycero-Phosphoethanolamines

Therapeutically active, heteroaryl-substituted deoxy glycero-phosphoethanolamines are disclosed having the general Formula I: STR1 wherein one of X, Y or Z is a fatty ether substituent, one is a heteroaryl ring substituent with 1-4 nitrogens as the only heteroatoms, one of which is bonded to a carbon of the glyceryl backbone, and one is a phosphoethanolamine substituent substituted at the nitrogen, provided that each of X, Y and Z is a different substituent, and the pharmaceutical compositions comprising the therapeutically active compounds and methods of using the therapetically active compounds to treat cancerous tumors, psoriasis and inflammation are also disclosed.

Lipid derivatives, their production and use

Novel lipid derivatives of the formula STR1 [wherein R1 is alkyl or alkylcarbamoyl; R2 is hydrogen, hydroxy which may be substituted, amino which may be substituted or cyclic amino; R3 is a chemical binding or alkylene which may be substituted; R4 is hydrogen, alkyl or aralkyl; X and Y are independently O, S or an imino group which may be substituted, and when Y is an imino group, Y, together with the imino group represented by X or R4, may form a ring; and Z is imino or a nitrogen-containing heterocyclic ring which may be substituted] and salts thereof have inhibiting activity on platelet activating factor and are useful as a preventive or therapeutic agent for a variety of circulatory diseases and allergic disorders and also as an antineoplastic agent.

Certain 3-alkoxy-2-cyclic-imido-propyl-phosphate-ethyl-cyclic ammonium hydroxide inner salts which inhibit activities of platelet activating factor

A novel phospholipid of the formula: STR1 wherein R1 is an alkyl group of 10 to 24 carbon atoms, R2 is a cyclic imide group and A+ is a cyclic ammonio group and a salt thereof have platelet activating factor inhibiting act